Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antigenics Inc.
Antigenics Reports First Quarter 2008 Financial Results
May 18th, 2008
Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended March 31, 2008. The company incurred a net loss attributable to common stockholders of $11.3 million, or $0.20 per share, basic and diluted, for the first quarter of 2008, compared with a net loss attributable to common stockholders in the first quarter of 2007 of $8.9 million, or $0.19 per share, basic and diluted. The company's net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the three months ended March 31, 2008 and 2007 was $9.4 million and $9.3 million, respectively. The 2008 results reflect, among other things, the company's efforts to obtain registration...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
